Actualités Oculis Holding AG - OCS | Actions NASDAQ

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs

Oculis establishes its US headquarters in Boston, MA, a world-renowned biotech hub, to support its continued...

Oculis to Participate at Upcoming Investor Conferences

ZUG, Switzerland and BOSTON, April 05, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a...

Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones

ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a...

Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing

ZUG, Switzerland, and BOSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”...

Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial

Completed enrollment in Phase 3 OPTIMIZE trial brings OCS-01 one step further on the regulatory path to...

Termination of Registration of a Class of Security Under Section 12(g) (15-12g)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM&nbs...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Oculis Holding AG (OCS)

Outils de qualité professionnelle, pour des investisseurs individuels.

OCS Actualités

Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs

Oculis to Participate at Upcoming Investor Conferences

Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones

Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing

Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial

Termination of Registration of a Class of Security Under Section 12(g) (15-12g)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Oculis Holding AG (OCS) Actualités

Oculis Holding AG (OCS)

Outils de qualité professionnelle, pour des investisseurs individuels.

OCS Actualités

Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs

Oculis to Participate at Upcoming Investor Conferences

Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones

Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing

Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial

Termination of Registration of a Class of Security Under Section 12(g) (15-12g)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application